Global Information
회사소개 | 문의 | 비교리스트

세계의 신종 코로나바이러스 감염증(COVID-19) 진단약 및 치료제 시장(-2025년) : PCR 검사, 항체 검사, 면역치료제, 백신, 항바이러스제, 세포치료제, 혈장 치료제

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

리서치사 Meticulous Market Research Pvt. Ltd.
발행일 2020년 07월 상품 코드 946876
페이지 정보 영문 100 Pages
가격
US $ 3,675 ₩ 4,393,000 PDF (Single User License)
US $ 6,475 ₩ 7,740,000 PDF (Multi User License)

주의 : 본 보고서는 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 신종 코로나바이러스 감염증(COVID-19) 진단약 및 치료제 시장(-2025년) : PCR 검사, 항체 검사, 면역치료제, 백신, 항바이러스제, 세포치료제, 혈장 치료제 COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025
발행일 : 2020년 07월 페이지 정보 : 영문 100 Pages

세계 각국의 보건부 및 의료 연구자는 신종 코로나바이러스 감염증(COVID-19)의 감염 확대 방지를 목표로 경쟁하며 솔루션을 모색하고 있습니다. 개발중인 치료제의 50% 이상은 여전히 전임상 단계이나, FDA에 의한 긴급사용승인(EUA) 등의 구상에 의해 R&D 프로세스가 가속할 것으로 기대되고 있습니다. COVID-19 진단약 및 치료제의 시장 기회는 2025년에 139억 달러 규모에 달할 것으로 예측되고 있습니다. 그 중에서도 백신 및 항바이러스제는 전 세계 연구자에 의해 현재 가장 많이 연구되고 있습니다.

세계의 신종 코로나바이러스 감염증(COVID-19) 진단약 및 치료제 시장을 조사했으며, 시장의 정의와 개요, COVID-19의 개요·현황, COVID-19 진단약 및 치료제의 파이프라인 동향, 지역별 영향과 개발에 대한 구상, 주요 기업에 의한 구상 등을 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 코로나바이러스 : 역학

제4장 개요

  • 서론
  • 세계 경제에 대한 영향
  • COVID-19에 대한 대응
  • COVID-19 : 연구 파이프라인
  • COVID-19 파이프라인상 과제
  • 주요 기업

제5장 Covid-19 : 의료 부문에 대한 영향

  • 서론
  • 주요 동향·상세 부문에 대한 영향
  • 진단약
    • PCR·신속 항원 검사·핵산 기반 검사
    • 항체 검사·혈청 검사
  • 치료제
    • 백신
    • 면역치료(항체)
    • 항바이러스제
    • 세포 기반 치료제
    • 기타

제6장 영향 분석 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제7장 경쟁 구도

  • 서론
  • 계약·거래·제휴·협업·JV
  • R&D의 최신 동향
  • 인가·승인
  • 기부
  • 투입 자금
  • 생산능력 확대
  • 기타 성장 전략

제8장 기업의 최신 동향

  • 기업 세분화
  • 진단약
    • Roche Holding Ag
    • Thermo Fisher Scientific, Inc.
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Cepheid(Subsidiary of Danaher Corporation)
  • 항바이러스제
    • Abbivie Corporation
    • Gilead Sciences, Inc.
    • Eli Lilly And Company
  • 백신 개발
    • Moderna, Inc.
    • Novavax, Inc
    • Medicago, Inc
    • Inovio Pharmaceuticals, Inc.
    • GlaxoSmithKline(GSK)
    • Sanofi S.A.
    • Johnson & Johnson
  • 면역치료
    • Sorrento Therapeutics, Inc.
    • Astrazeneca Plc
    • Pfizer, Inc.
    • Cti Biopharma Corporation
    • Oncoimmune, Inc.
  • 세포치료
    • Athersys, Inc.
    • Cellularity, Inc.
    • Pluristem Therapeutics, Inc.
  • 혈장 요법
    • Takeda Pharmaceutical Company Ltd
KSA 20.07.20

List of Tables

  • Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19
  • Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 5 PCR Cycle and Corresponding No. of Target Copies Produced
  • Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021-2025 ($Million)
  • Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 18 Plasma Therapies in Pipeline for COVID-19
  • Table 19 COVID-19 Devices Platforms in Pipeline
  • Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)
  • Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019-2025 ($Million)
  • Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 26 Key Economic Indicators: Europe (2019 - 2021)
  • Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019-2025 ($Million)
  • Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 30 Key Economic Indicators: Asia (2019 - 2021)
  • Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 3 Market Size Estimation Methodology: Top-Down Approach
  • Figure 4 Research Design
  • Figure 5 Data Triangulation Methodology
  • Figure 6 Global Coronavirus Cases, As of 15 May 2020
  • Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))
  • Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)
  • Figure 9 Life Sciences Market Segmentation Impacted by Covid-19
  • Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage
  • Figure 11 Vaccine Pipeline, by Category & Development Stage
  • Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)
  • Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)
  • Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)
  • Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)
  • Figure 16 Key Growth Strategies, by Development & by Company, Feb - May 2020
  • Figure 17 Key Firms Active in COVID-19 Product Development

The healthcare systems have been struggling to manage the COVID-19 patient population globally and hence the medical researchers are racing to find a solution to the pandemic. According to this latest publication from Meticulous Research®, the leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. While more than 50% of the therapies being developed are in preclinical stage, government initiatives, such as Emergency Use Authorization (EUA) by FDA, is expected to accelerate the research and development (R&D) process.

Based on healthcare options, the COVID-19 impact assessment is analyzed into diagnostics and treatments areas. The market opportunity of these products is estimated to reach USD 13.9 billion in 2025. The diagnostics segment is further divided into PCR-based testing and antibody testing. The treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.

Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as well as deaths, globally. Other most affected nations include the U.K., Spain, France, Italy, Brazil, Germany, and India among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, increase in unemployment rates, and increase in the inflation rates. To overcome the situation, governments have imposed restriction on people movement as well as invested resources towards dealing with crisis and supporting all research and medical efforts towards developing a treatment option. The U.S., Canada, the U.K., Germany, China, and India are some of the key nations leading the research and production efforts geared towards developing COVID-19 medication.

Some of the key players engaged in COVID-19 diagnostics and treatment development include: Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline

  • Diagnosis
    • PCR Testing
    • Antibody Testing
  • Treatment
    • Vaccines
    • Immunotherapy
    • Antiviral
    • Cell-based Therapy
    • Other Therapies

COVID-19: Impact on Healthcare Industry

  • Diagnostics
    • Rapid Test Kits
    • PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
  • Advantages Offered by PCR Testing in COVID -19 Diagnosis
  • Restraints
  • Key Companies
    • Antibody Testing / Serological Testing
  • Advantages Over Molecular Tests
  • Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
  • Restraints
  • Key Companies
    • Therapies
  • Vaccines
  • Immunotherapies (Antibodies)
  • Monoclonal Antibody
  • T-Cell Therapy
  • Potential Game Changers: Antibodies
  • Ilaris (Canakinumab)
  • Sylvant (Siltuximab)
  • Lenzilumab
  • Ultomiris (Ravulizumab-Cwvz)
  • Tocilizumab
  • Anti-Virals
  • Potential Game Changers
  • Chloroquine and Hydroxychloroquine (HCQ)
  • Remdesivir
  • Cell-Based Therapies
  • Other Therapies
  • Plasma Therapy
  • Devices

COVID-19 Industry Impact Assessment, by Geography

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World (RoW)

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Markets Covered
  • 1.3. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Key Stakeholders

2. Research Methodology

  • 2.1. Research Methodology Steps
  • 2.2. Secondary and Primary Research Methodology
    • 2.2.1. Secondary Research
      • 2.2.1.1. Key Data from Secondary Sources
    • 2.2.2. Primary Research
      • 2.2.2.1. Key Data from Primary Sources
      • 2.2.2.2. Key Insights from Primary Sources
  • 2.3. Market Size Estimation Methodology
  • 2.4. Market Forecast Methodology
  • 2.5. Market Breakdown and Data Triangulation

3. Coronavirus: Epidemiology

  • 3.1. About Coronavirus
  • 3.2. Transmission & Symptoms
  • 3.3. Prevention
  • 3.4. Epidemiology

4. Executive Summary

  • 4.1. Introduction
  • 4.2. Global Economic Impact
  • 4.3. COVID-19 Response
  • 4.4. COVID-19 Research Pipeline
  • 4.5. COVID-19 Pipeline Development Challenges
  • 4.6. Key Companies

5. Covid-19: Impact on Healthcare Industry

  • 5.1. Introduction
  • 5.2. Key Trends & Impact on Healthcare Subsegments
  • 5.3. Diagnostics
    • 5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
      • 5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
      • 5.3.1.2. Restraints
      • 5.3.1.3. Key Companies
    • 5.3.2. Antibody Testing / Serological Testing
      • 5.3.2.1. Advantages Over Molecular Tests
      • 5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
      • 5.3.2.3. Restraints
      • 5.3.2.4. Key Companies
  • 5.4. Therapies
    • 5.4.1. Vaccines
    • 5.4.2. Immunotherapies (Antibodies)
      • 5.4.2.1. Monoclonal Antibody
      • 5.4.2.2. T-Cell Therapy
      • 5.4.2.3. Potential Game Changers: Antibodies
        • 5.4.2.3.1. Ilaris (Canakinumab)
        • 5.4.2.3.2. Sylvan (Siltuximab)
        • 5.4.2.3.3. Lenzilumab
        • 5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
        • 5.4.2.3.5. Tocilizumab
    • 5.4.3. Antivirals
      • 5.4.3.1. Potential Game Changers
        • 5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
        • 5.4.3.1.2. Remdesivir
    • 5.4.4. Cell-Based Therapies
    • 5.4.5. Other Therapies
      • 5.4.5.1. Plasma Therapy
      • 5.4.5.2. Devices

6. Geography Impact Assessment

  • 6.1. Introduction
    • 6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
  • 6.2. North America
    • 6.2.1. COVID-19 Impact on the U.S. Economy
    • 6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment
    • 6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages
    • 6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government
    • 6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics
    • 6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada
  • 6.3. Europe
    • 6.3.1. Economic Impact of COVID-19: European Nations
    • 6.3.2. European Firms to Lead the COVID-19 Treatment Researches
    • 6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19
    • 6.3.4. Partnership of European Pharmaceutical Giants - Sanofi and GSK To Develop COVID-19 Vaccine
    • 6.3.5. German Vaccine Became the First European MRNA Vaccine to Enter Human Testing
    • 6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19
  • 6.4. APAC
    • 6.4.1. Economic Impact of COVID-19: APAC
    • 6.4.2. Asian Countries Leading the Diagnostics Test Commercialization
    • 6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine
    • 6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain
  • 6.5. Rest of the World
    • 6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil
    • 6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development
    • 6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa

7. Competitive Landscape

  • 7.1. Introduction
  • 7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
  • 7.3. R&D Updates
  • 7.4. Auhrozation / Approvals
  • 7.5. Donations Made
  • 7.6. Funding Received
  • 7.7. Capacity Expansion
  • 7.8. Other Growth Strategies

8. Company Updates

  • 8.1. Company Segmentation
  • 8.2. Diagnostic Companies
    • 8.2.1. Roche Holding Ag
      • 8.2.1.1. About the Firm
      • 8.2.1.2. COVID-19 Pipeline
      • 8.2.1.3. Recent Developments
    • 8.2.2. Thermo Fisher Scientific, Inc.
      • 8.2.2.1. About the Firm
      • 8.2.2.2. COVID-19 Pipeline
      • 8.2.2.3. Recent Developments
    • 8.2.3. Becton, Dickinson and Company
      • 8.2.3.1. About the Firm86
      • 8.2.3.2. COVID-19 Pipeline
      • 8.2.3.3. Recent Developments
    • 8.2.4. Abbott Laboratories
      • 8.2.4.1. About the Firm
      • 8.2.4.2. COVID-19 Pipeline
      • 8.2.4.3. Recent Developments
    • 8.2.5. Cepheid (Subsidiary of Danaher Corporation)
      • 8.2.5.1. About the Firm
      • 8.2.5.2. COVID-19 Pipeline
      • 8.2.5.3. Recent Developments
  • 8.3. Antivirals
    • 8.3.1. Abbivie Corporation
      • 8.3.1.1. About the Firm
      • 8.3.1.2. COVID-19 Pipeline
      • 8.3.1.3. Recent Developments
    • 8.3.2. Gilead Sciences, Inc.
      • 8.3.2.1. About the Firm
      • 8.3.2.2. Covid-19- Pipeline
      • 8.3.2.3. Recent Developments
    • 8.3.3. Eli Lilly And Company
      • 8.3.3.1. About the Firm
      • 8.3.3.2. Covid-19- Products
      • 8.3.3.3. Recent Developments
  • 8.4. Vaccine Developers
    • 8.4.1. Moderna, Inc.
      • 8.4.1.1. About the Firm
      • 8.4.1.2. COVID-19 Pipeline
      • 8.4.1.3. Recent Developments
    • 8.4.2. Novavax, Inc
      • 8.4.2.1. About the Firm
      • 8.4.2.2. COVID-19 Pipeline
      • 8.4.2.3. Recent Developments
    • 8.4.3. Medicago, Inc
      • 8.4.3.1. About the Firm
      • 8.4.3.2. COVID-19 Pipeline
      • 8.4.3.3. Recent Developments
    • 8.4.4. Inovio Pharmaceuticals, Inc.
      • 8.4.4.1. About the Firm
      • 8.4.4.2. COVID-19 Pipeline
      • 8.4.4.3. Recent Developments
    • 8.4.5. GlaxoSmithKline (GSK)
      • 8.4.5.1. About the Firm
      • 8.4.5.2. COVID-19 Pipeline
      • 8.4.5.3. Recent Developments
    • 8.4.6. Sanofi S.A.
      • 8.4.6.1. About the Firm
      • 8.4.6.2. COVID-19 Pipeline
      • 8.4.6.3. Recent Developments
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. About the Firm
      • 8.4.7.2. COVID-19 Pipeline
      • 8.4.7.3. Recent Developments
  • 8.5. Immunotherapy Firms
    • 8.5.1. Sorrento Therapeutics, Inc.
      • 8.5.1.1. About the Firm
      • 8.5.1.2. COVID-19 Pipeline
      • 8.5.1.3. Recent Developments
    • 8.5.2. Astrazeneca Plc
      • 8.5.2.1. About the Firm
      • 8.5.2.2. COVID-19 Pipeline
      • 8.5.2.3. Recent Developments
    • 8.5.3. Pfizer, Inc.
      • 8.5.3.1. About the Firm
      • 8.5.3.2. COVID-19 Pipeline
      • 8.5.3.3. Recent Developments
    • 8.5.4. Cti Biopharma Corporation
      • 8.5.4.1. About the Firm
      • 8.5.4.2. COVID-19 Pipeline
      • 8.5.4.3. Recent Developments
    • 8.5.5. Oncoimmune, Inc.
      • 8.5.5.1. About the Firm
      • 8.5.5.2. COVID-19 Pipeline
      • 8.5.5.3. Recent Developments
  • 8.6. Cell-Based Therapy
    • 8.6.1. Athersys, Inc.
      • 8.6.1.1. About the Firm
      • 8.6.1.2. COVID-19 Pipeline
      • 8.6.1.3. Recent Developments
    • 8.6.2. Cellularity, Inc.
      • 8.6.2.1. About the Firm
      • 8.6.2.2. COVID-19 Pipeline
      • 8.6.2.3. Recent Developments
    • 8.6.3. Pluristem Therapeutics, Inc.
      • 8.6.3.1. About the Firm
      • 8.6.3.2. COVID-19 Pipeline
      • 8.6.3.3. Recent Developments
  • 8.7. Plasma Therapy
    • 8.7.1. Takeda Pharmaceutical Company Ltd
      • 8.7.1.1. About the Firm
      • 8.7.1.2. COVID-19 Pipeline
      • 8.7.1.3. Recent Developments
Back to Top
전화 문의
F A Q